Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism.

ABSTRACT:

Objective

The purpose of this study was to determine whether polymorphisms in the serotonin transporter (SLC6A4) and serotonin-2A receptor (HTR2A) genes are associated with response to escitalopram in patients with autism spectrum disorder (ASD).

Methods

Forty-four participants with ASD were enrolled in a 6 week, forced titration, open label examination of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Doses increased at weekly intervals starting at 2.5mg daily with a maximum possible dose of 20 mg daily achieved by the end of the study. If adverse events were experienced, participants subsequently received the previously tolerated dose for the duration of study. SLC6A4 (5-HTTLPR) and HTR2A (rs7997012) genotype groups were assessed in relation to treatment o

SUBMITTER: Najjar F 

PROVIDER: S-EPMC4544820 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature